Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neihulizumab in Refractory Ulcerative Colitis
NCT03298022Phase 2Terminated
- Sponsor
- AltruBio Inc.
- Start
- May 2018
- Primary completion
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of neihulizumab in ulcerative colitis (UC), sponsored by AltruBio Inc.. Started May 2018; status: terminated.
02
Drugs
neihulizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03298022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298022.